Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT05262023
PHASE1/PHASE2

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia (FTD-GRN)

Sponsor: Denali Therapeutics Inc.

View on ClinicalTrials.gov

Summary

This is a Phase 1/2, multicenter, randomized, placebo-controlled, double-blind study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple doses of DNL593 in two parts followed by an optional open-label extension (OLE) period. Part A will evaluate the safety, tolerability, PK, and PD of single doses of DNL593 in healthy male and healthy female participants of nonchildbearing potential. Part B will evaluate the safety, tolerability, PK, and PD of multiple doses of DNL593 in participants with frontotemporal dementia (FTD) over 25 weeks. Part B will be followed by Part C, an optional 18-month OLE period available for all participants who complete Part B.

Official title: A Phase 1/2, Multicenter, Randomized, Placebo-Controlled, Double Blind Single Dose and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia Followed by an Open-Label Extension

Key Details

Gender

All

Age Range

18 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

85

Start Date

2022-02-01

Completion Date

2028-11

Last Updated

2026-01-15

Healthy Volunteers

Yes

Interventions

DRUG

DNL593

Ascending single doses (for healthy participants) and multiple doses (for participants with FTD)

DRUG

Placebo

Ascending single doses (for healthy participants) and multiple doses (for participants with FTD)

Locations (26)

University of California San Francisco

San Francisco, California, United States

John Hopkins University

Baltimore, Maryland, United States

Hospital of the University of Pennsylvania

Philadelphia, Pennsylvania, United States

University of Antwerp

Antwerp, Belgium

UZ Leuven

Leuven, Belgium

L2IP - Instituto de Pesquisas Clinicas LTDA

Brasília, Brazil

Faculdade de Medicina Da Universidade de São Paulo

São Paulo, Brazil

Hospital Universitario San Ignacio

Bogotá, Colombia

Grupo de Neurosicencias de la Universidad de Antioquia

Medellín, Colombia

Fakultni nemocnice v Motole

Prague, Czechia

CHU de Nantes

Nantes, France

CHU Rouen

Rouen, France

CHU Toulouse

Toulouse, France

ASST degli Spedali Civili di Brescia

Brescia, Italy

Azienda Ospedaliera Universitaria Careggi

Florence, Italy

IRCCS Istituto Auxologico Italiano

Milan, Italy

Azienda Ospedaliera Cardinale G Panico

Tricase, Italy

Erasmus University Medical Center

Rotterdam, Netherlands

Hospital de Braga

Braga, Portugal

Campus Neurológico Sénior

Torres Vedras, Portugal

Hospital Clinic de Barcelona

Barcelona, Barcelona, Spain

Hospital Universitario de Donostia

Donostia / San Sebastian, Guipúzcoa, Spain

Hospital Universitario Virgen del Rocio

Seville, Sevilla, Spain

Istanbul University Istanbul Medical Faculty

Istanbul, Turkey (Türkiye)

Ondokuz Mayis University Hospital

Samsun, Turkey (Türkiye)

Simbec Orion

Merthyr Tydfil, Wales, United Kingdom